Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGamma Communications Regulatory News (GAMA)

Share Price Information for Gamma Communications (GAMA)

Share Price is delayed by 15 minutes
Get Live Data
945.50    2.00 (0.21%)
Bid:
950.00
Ask:
950.50
Spread: 0.50 (0.053%)
Market Cap: £853.23m
GAMA Live PriceLast checked at - London Stock Exchange

Intraday Gamma Communications Share Chart

Trading Statement

12 Jan 2022 07:00

RNS Number : 1299Y
Gamma Communications PLC
12 January 2022
 

12 January 2022

Gamma Communications plc

Trading Update

 

Full year adj EBITDA and adj EPS anticipated to be in the top half of the range of market expectations

 

Gamma Communications plc ("Gamma"), a leading provider of Unified Communication as a Service ("UCaaS") products, announces a trading update for the year ended 31 December 2021.

 

Trading

There is a continued strong demand in the UK and European business markets for Gamma's portfolio of UCaaS products, which through both Direct and Indirect channels have performed well throughout the trading period.

 

Market expectations were raised following the announcement of Gamma's trading updates issued on 20 May and 13 July 2021. The Board expects that revenue for the year ended 31 December 2021 will be within the range of current market expectations and adjusted EBITDA and adjusted EPS will be in the upper half of current market expectations*. 

 

Cash

The closing net cash balance was £49.5m (2020: £48.0m) which was ahead of expectations due to a strong working capital performance. The year on year net cash increase is particularly pleasing given that during 2021 Gamma spent £49.3m on acquisitions (primarily the acquisition of Mission Labs), increased investment in product development compared to 2020 and paid dividends to shareholders totalling £11.7m (2020:£10.4m), a year on year increase of 12.5%.

 

Overview of the year

 

Some of the highlights from the year include:

 

· The group performed strongly throughout 2021 despite the ongoing economic uncertainty caused by Covid-19. Gamma's recurring revenue model has proved robust, and importantly, its product set supports businesses which have a need to both operate and work remotely.

· Unit sales of our core UCaaS products have continued to be strong in both the UK and Europe.

· In our Direct business we have won several new multi-year contracts, including The Berkeley Group (Horizon Contact), NFU Mutual (SDWAN) and also a large central Government department (fully managed Microsoft Teams deployment).

· In March, Gamma acquired Mission Labs bringing additional technology and product capabilities to the Group (Smart Agent and Circle Loop) as well as adding important software development capabilities. The integration of Mission Labs has gone well and is proceeding in line with expectations. Gamma is leveraging Mission Labs' relationship with Amazon to expand its offering into the Enterprise market through the Smart Agent product, which has generated new customers during the period. The Circle Loop product (which is a digitally based Cloud PBX product aimed at the micro business market) is also growing in line with expectations. Moreover, the Mission Labs team is working well with the existing Gamma technology and product teams which have collectively accelerated progress on product and feature development.

· The Group has continued to develop its suite of products and has launched Horizon Contact (which is a Contact Centre as a Service product) and has integrated Microsoft Teams to its market leading Horizon Cloud PBX product.

· Gamma has continued to develop its relationship with Microsoft and launched Microsoft Teams Direct Routing in March - essentially a SIP Trunk which works specifically with Teams. Gamma was also added to Microsoft's select list of carriers who offer the "Operator Connect" service which is designed to enable seamless and integrated calling between Teams and the local telephony infrastructure (known as the PSTN). This selection demonstrates the strength of Gamma having both a UCaaS offering as well as an ability to provide integration to the PSTN.

 

The Board expects to announce results for the year ended 31 December 2021 on Tuesday 22 March.

 

*Company compiled market expectations for the full year ended 31 December 2021 are revenue (£444.5m-£455.6m), adjusted EBITDA (£90.5m-£96.0m) and adjusted EPS (57.6p-64.0p).

 

 

Andrew Taylor, Chief Executive, commented:

"We are pleased that Gamma has grown very strongly throughout 2021 while continuing to invest significantly in our business and executing against all aspects of our strategic plan. The demand for cloud communications across all geographies and market segments is positive and the long-term growth opportunity for Gamma is very significant.

 

"Our UCaaS product strategy is progressing very well, and we are pleased with the overall performance of our product set, in particular the new products which we launched through the year. Our product set, digital channel and software development capabilities have been strengthened with the acquisition of Mission Labs and we are very pleased with how this is performing.

 

"I would like to take this opportunity to personally thank our staff and partners for all of their support and hard work throughout the year."

 

END

 

Gamma Communications plc

Andrew Taylor, Chief Executive Officer

Andrew Belshaw, Chief Financial Officer

Tel: +44 (0) 333 006 5972

 

 

Tulchan Communications LLP

James Macey White / Matt Low

Tel: +44 (0) 207 353 4200

 

 

Investec Bank plc (NOMAD & Broker)

Tel: +44 (0) 207 597 5970

Patrick Robb / Virginia Bull

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGMMNMDGZZM
Date   Source Headline
16th Mar 20237:00 amRNSDirectorate Change
14th Mar 20239:43 amRNSDirector/PDMR Shareholding
1st Mar 20232:01 pmRNSTotal Voting Rights
1st Mar 20239:32 amRNSHolding(s) in Company
17th Feb 20237:30 amRNSDirector/PDMR Shareholding
1st Feb 20235:47 pmRNSTotal Voting Rights
27th Jan 202312:44 pmRNSHolding(s) in Company
18th Jan 20235:21 pmRNSHolding(s) in Company
17th Jan 202310:34 amRNSDirector/PDMR Shareholding
12th Jan 20237:00 amRNSFull year growth expectations remain unchanged
11th Jan 20232:30 pmRNSTotal Voting Rights
11th Jan 20231:28 pmRNSHolding(s) in Company
10th Jan 202311:47 amRNSHolding(s) in Company
6th Jan 20234:08 pmRNSHolding(s) in Company
20th Dec 20227:00 amRNSChange of Senior Independent Director
19th Dec 202211:58 amRNSHolding(s) in Company
16th Dec 20223:31 pmRNSHolding(s) in Company
15th Dec 20226:26 pmRNSDirector/PDMR Shareholding
5th Dec 20225:15 pmRNSTotal Voting Rights
30th Nov 20227:00 amRNSChief Executive Officer Appointment
15th Nov 20226:04 pmRNSDirector/PDMR Shareholding
15th Nov 20223:44 pmRNSHolding(s) in Company
9th Nov 20228:53 amRNSBlock listing Interim Review
8th Nov 20222:17 pmRNSHolding(s) in Company
1st Nov 20223:18 pmRNSTotal Voting Rights
28th Oct 20224:54 pmRNSChange of Registered Office
27th Oct 20224:49 pmRNSDirector/PDMR Shareholding
17th Oct 20226:23 pmRNSDirector/PDMR Shareholding
13th Oct 20222:14 pmRNSHolding(s) in Company
10th Oct 202211:29 amRNSDirector/PDMR Shareholding
3rd Oct 20225:59 pmRNSTotal Voting Rights
3rd Oct 20224:44 pmRNSNon-Executive Director Appointment
27th Sep 20222:44 pmRNSDirector/PDMR Shareholding
15th Sep 202211:13 amRNSHolding(s) in Company
13th Sep 20224:52 pmRNSDirector/PDMR Shareholding
7th Sep 20226:10 pmRNSHolding(s) in Company
6th Sep 20227:00 amRNSHalf-year Report
31st Aug 20224:04 pmRNSHolding(s) in Company
16th Aug 202211:52 amRNSDirector/PDMR Shareholding
5th Aug 20225:23 pmRNSHolding(s) in Company
3rd Aug 202210:09 amRNSHolding(s) in Company
2nd Aug 20222:18 pmRNSTotal Voting Rights
2nd Aug 202210:25 amRNSHolding(s) in Company
2nd Aug 20227:00 amRNSH1 Trading Update
22nd Jul 20224:44 pmRNSHolding(s) in Company
21st Jul 20225:38 pmRNSHolding(s) in Company
19th Jul 20225:06 pmRNSDirector/PDMR Shareholding
13th Jul 20226:07 pmRNSDirector/PDMR Shareholding
8th Jul 20224:39 pmRNSIssue of Equity
6th Jul 20224:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.